Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 361
- Registration Number
- NCT00157248
- Locations
- 🇺🇸
1160.42.10013 Boehringer Ingelheim Investigational Site, New Hyde Park, New York, United States
🇳🇱1160.42.31008 Gelre Ziekenhuis, locatie Juliana, Apeldoorn, Netherlands
🇩🇰1160.42.45005 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20332
- Registration Number
- NCT00153062
- Locations
- 🇺🇸
9.159.1197 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
🇺🇸9.159.1024 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸9.159.1005 Boehringer Ingelheim Investigational Site, Fort Smith, Arkansas, United States
Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 472
- Registration Number
- NCT00152984
- Locations
- 🇧🇪
Clinique Reine Astrid, Malmedy, Belgium
🇧🇪Sint-Elisabethziekenhuis, Turnhout, Belgium
🇫🇷Hopital Notre Dame de Bon Secours, Metz cedex 1, France
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT00153075
- Locations
- 🇩🇪
Inamed Research GmbH & Co. KG, Gauting, Germany
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 31546
- Registration Number
- NCT00153101
- Locations
- 🇺🇸
502.373.0247 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸502.373.0177 Boehringer Ingelheim Investigational Site, Tuscon, Arizona, United States
🇦🇺502.373.0529 Launceston General Hospital, Launceston, Tasmania, Australia
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 254
- Registration Number
- NCT00148512
- Locations
- 🇩🇪
Paracelsus-Elena-Klinik, Kassel, Germany
🇦🇹Univ.-Klinik für Neurologie, Innsbruck, Austria
🇫🇷Hôpital Gabriel Montpied, Clermont Ferrand, France
Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 270
- Registration Number
- NCT00148460
- Locations
- 🇰🇷
Dongsan Medical Center, Jung-Ku, Korea, Republic of
🇰🇷Chunnam University Hospital, Kwang-Ju, Korea, Republic of
🇨🇳Beijing University, Beijing, China
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 261
- Registration Number
- NCT00148486
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇨🇦Davidson Memory Clinic, Moncton, New Brunswick, Canada
🇨🇦Centre For Movement Disorders, Markham, Ontario, Canada
Efficacy and Tolerability of Ambroxol Lozenge 20 mf in Relieving Pain of Sore Throat in Pat. With Acute/Viralpharyngitis
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 751
- Registration Number
- NCT00148499
- Locations
- 🇷🇴
Medicover, Bucharest, Romania
🇺🇦City Clinical Otolaryngological Hospital, Kharkov, Ukraine
🇷🇴Victor Babes Clincial Hospital, Bucharest, Romania
The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 138
- Registration Number
- NCT00146289
- Locations
- 🇨🇦
St. Joseph's Health Care London, London, Ontario, Canada
🇩🇪Universitätsmedizin Berlin, Berlin, Germany
🇩🇪Boehringer Ingelheim Investigational Site, Unterschneidheim, Germany